Nasdaq. The Company shall have submitted a listing of additional shares notification form to Nasdaq with respect to the Offered Shares and shall have received no objection thereto from Nasdaq.
Appears in 30 contracts
Sources: Underwriting Agreement (Celldex Therapeutics, Inc.), Underwriting Agreement (Veru Inc.), Underwriting Agreement (Celldex Therapeutics, Inc.)
Nasdaq. The Company shall have submitted a listing of additional shares notification form to Nasdaq with respect to the Offered Shares Securities and shall have received no objection thereto from Nasdaq.
Appears in 3 contracts
Sources: Placement Agency Agreement, Placement Agency Agreement (Evogene Ltd.), Placement Agency Agreement (Cidara Therapeutics, Inc.)
Nasdaq. The Company shall have submitted a listing of additional shares notification form to Nasdaq with respect to the Offered Shares and shall have received no objection to list thereto from Nasdaq.
Appears in 3 contracts
Sources: Underwriting Agreement (Wave Life Sciences Ltd.), Underwriting Agreement (Wave Life Sciences Ltd.), Underwriting Agreement (Wave Life Sciences Ltd.)
Nasdaq. The Company shall have submitted a listing of additional shares notification form to Nasdaq with respect to the Offered Shares and shall have received no objection thereto from NasdaqShares.
Appears in 2 contracts
Sources: Underwriting Agreement (Roivant Sciences Ltd.), Underwriting Agreement (Alaunos Therapeutics, Inc.)
Nasdaq. The Company shall have submitted a listing of additional shares notification form to Nasdaq with respect to the Offered Shares Securities and shall have received no objection thereto from Nasdaq.
Appears in 2 contracts
Sources: Underwriting Agreement (Zosano Pharma Corp), Underwriting Agreement (Polarityte, Inc.)
Nasdaq. The Company shall have submitted a listing of additional shares notification form to Nasdaq with respect to the Offered Shares and shall have received no objection thereto from Nasdaq.
Appears in 2 contracts
Sources: Underwriting Agreement (Aptinyx Inc.), Underwriting Agreement (Aptinyx Inc.)
Nasdaq. The Company shall have submitted a listing of additional shares notification form to Nasdaq with respect to the Offered Shares and the Warrant Shares and shall have received no objection to list thereto from Nasdaq.
Appears in 2 contracts
Sources: Underwriting Agreement (Wave Life Sciences Ltd.), Underwriting Agreement (Wave Life Sciences Ltd.)
Nasdaq. The Company shall have submitted a listing of additional shares notification form to the Nasdaq with respect to the Offered Shares and shall have received no objection thereto from the Nasdaq.
Appears in 1 contract
Nasdaq. The Company shall have submitted a listing of additional shares notification form to Nasdaq with respect to the Offered Shares and the Warrant Shares and shall have received no objection thereto from Nasdaq.
Appears in 1 contract
Sources: Underwriting Agreement (Ekso Bionics Holdings, Inc.)
Nasdaq. The Company shall have submitted a listing of additional shares notification form to Nasdaq with respect to the Offered Shares (including the Warrant Shares) and shall have received no objection thereto from Nasdaq.
Appears in 1 contract
Nasdaq. The Company shall have submitted a listing of additional shares notification form to Nasdaq with respect to the Offered Shares (including the Warrant Shares) and shall have received no objection thereto from Nasdaq.
Appears in 1 contract
Sources: Underwriting Agreement (Veru Inc.)
Nasdaq. The Company shall have submitted a listing of additional shares notification form to Nasdaq with respect to the Offered Shares and Warrant Shares and shall have received no objection thereto from Nasdaq.
Appears in 1 contract